TCG Advisory Services LLC Purchases 65,391 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

TCG Advisory Services LLC raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4,938.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 66,715 shares of the medical equipment provider’s stock after acquiring an additional 65,391 shares during the quarter. Intuitive Surgical makes up about 1.5% of TCG Advisory Services LLC’s investment portfolio, making the stock its 10th largest holding. TCG Advisory Services LLC’s holdings in Intuitive Surgical were worth $22,507,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. First National Trust Co raised its stake in Intuitive Surgical by 3.8% in the 4th quarter. First National Trust Co now owns 3,127 shares of the medical equipment provider’s stock valued at $1,055,000 after acquiring an additional 115 shares during the period. AJOVista LLC bought a new position in shares of Intuitive Surgical in the fourth quarter valued at about $200,000. Provence Wealth Management Group acquired a new stake in shares of Intuitive Surgical during the 4th quarter worth about $276,000. Blue Fin Capital Inc. boosted its holdings in shares of Intuitive Surgical by 8.0% during the 4th quarter. Blue Fin Capital Inc. now owns 864 shares of the medical equipment provider’s stock worth $291,000 after buying an additional 64 shares during the period. Finally, Legacy Financial Advisors Inc. grew its stake in Intuitive Surgical by 13.9% in the 4th quarter. Legacy Financial Advisors Inc. now owns 1,774 shares of the medical equipment provider’s stock valued at $598,000 after buying an additional 216 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Up 1.0 %

NASDAQ ISRG traded up $3.71 during trading on Friday, hitting $381.36. 1,028,858 shares of the company’s stock were exchanged, compared to its average volume of 1,492,254. The stock’s 50 day moving average price is $385.40 and its two-hundred day moving average price is $349.30. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The company has a market cap of $135.27 billion, a PE ratio of 68.84, a P/E/G ratio of 4.93 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm’s revenue was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.00 EPS. Analysts forecast that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. StockNews.com cut Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Raymond James increased their price objective on Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Mizuho boosted their target price on shares of Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Barclays lifted their price objective on shares of Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Finally, Piper Sandler increased their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research report on Friday, April 19th. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $396.17.

Insider Activity at Intuitive Surgical

In other news, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the sale, the vice president now directly owns 26,877 shares in the company, valued at $10,349,795.16. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Marshall Mohr sold 108,790 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares in the company, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. Insiders have sold a total of 226,928 shares of company stock valued at $87,833,828 in the last 90 days. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.